Jahresbericht 2023/24

Publikationen

• Adamowicz K, Arend L, Maier A, Schmidt J R, Kuster B, Tsoy O, Zolotareva O, Baumbach J, Laske T. Proteomic meta-study harmonization, mechanotyping and drug repurposing candidate prediction with ProHarMeD. NPJ Syst Biol Appl 2023, 9(1): 49. doi: 10.1038/s41540-023-00311-7
• Agarwal B, Cañizares RB, Saliba F, Ballester MP, Tomescu DR, Martin D, Stadlbauer V, Wright G, Sheikh M, Morgan C, Alzola C, Lavin P, Green D, Kumar R, Sacleux SC, Schilcher G, Koball S, Tudor A, Minten J, Domenech G, Aragones JJ, Oettl K, Paar M, Waterstradt K, Bode-Boger SM, Ibáñez-Samaniego L, Gander A, Ramos C, Chivu A, Stange J, Lamprecht G, Sanchez M, Mookerjee RP, Davenport A, Davies N, Pavesi M, Andreola F, Albillos A, Cordingley J, Schmidt H, Carbonell-Asins JA, Arroyo V, Fernandez J, Mitzner S, Jalan R. Randomized, controlled clinical trial of the DIALIVE liver dialysis device versus standard of care in patients with acute-on- chronic liver failure. J Hepatol. 2023, Jul;79(1): 79-92. doi: 10.1016/j.jhep.2023.03.013
  
• Ammar D, Schapitz I, Luu M, Hudecek M, Meyer M, Taps T, Schröder B, Ivics Z, Sanges C, Franz P, Koehl U, Negre H, Johanna I, Awigena-Cook J. Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations. Front Immunol. 2023, Nov, 14: 1280826. doi: 10.3389/fimmu.2023.1280826
  
• Anders I M, Schimmelpfennig C, Wiedemann K, Löffler D, Kämpf C, Blumert C, Reiche K, Kunz M, Anderegg U, Simon J-C, Ziemer M. Atypical fibroxanthoma and pleomorphic dermal sarcoma – gene expression analysis compared with undifferentiated cutaneous squamous cell carcinoma. J Dtsch Dermatol Ges 2023, 21 (5): 482-491. doi: 10.1111/ddg.15006
  
• Auw N von, Serfling R, Kitte R, Hilger N, Zhang C, Gebhardt C, Dünkel A, Franz P, Köhl U, Fricke S, Tretbar SU. Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality. Sci Rep 2023, 13 (1), article 18160. doi: 10.1038/s41598-023-45197-x
  
• Bache M, Kadler F, Struck O, Medenwald D, Ostheimer C, Güttler A, Keßler J, Kappler M, Riemann A, Thews O, Seliger B, Vordermark D. Correlation between circulating miR-16, miR-29a, miR-144 and miR-150, and the radiotherapy response and survival of non-small-cell lung cancer patients. Int J Mol Sci 2023, 24 (16), article 12835. doi: 10.3390/ijms241612835
  
• Barendrecht S, Schreurs A, Geißler S, Sabanov V, Ilse V, Rieckmann V, Eichentopf R, Künemund A, Hietel B, Wussow S, Hoffmann K, Körber-Ferl K, Pandey R, Carter G W, Demuth H-U, Holzer M, Roßner S, Schilling S, Preuss C, Balschun D, Cynis H. A novel human tau knock-in mouse model reveals interaction of Abeta and human tau under progressing cerebral amyloidosis in 5xFAD mice. Alzheimers Res Ther 2023, 15 (1), article 16. doi: 10.1186/s13195-022-01144-y
  
• Bentler M, Hardet R, Ertelt M, Rudolf D, Kaniowska D, Schneider A, Vondran F W R, Schoeder C T, Delphin M, Lucifora J, Ott M, Hacker U T, Adriouch S, Büning H. Modifying immune responses to adeno-associated virus vectors by capsid engineering. Mol Ther Methods Clin Dev 2023, 30: 576-592. doi: 10.1016/j.omtm.2023.08.015
  
• Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD open 2023, 9 (4): e002907. doi: 10.1136/rmdopen-2022-002907
• Blaudszun A-R, Kim W J, Um W, Yoon H Y, Shim M K, Kim K. Adoptive transfer of photosensitizer-loaded cytotoxic T cells for combinational photodynamic therapy and cancer immuno-therapy. Pharmaceutics. 2023,15 (4): 1295. doi: 10.3390/pharmaceutics15041295
  
• Böhm K, Schulze-Niemand E, Kähne T, Siddiqui E, Täger C, Ramsbeck D, Buchholz M, Naumann M. Synthesis and structure–activity relationships of USP48 deubiquitinylase inhibitors. Arch Pharm 2023, 356 (7), article: 2200661. doi: 10.1002/ardp.202200661
• Broséus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, Schneider C, Dartigeas C, Roos-Weil D, Quinquenel A, Moulin C, Ott G, Blanchet O, Tomowiak C, Lazarian G, Rouyer P, Chteinberg E, Bernhart SH, Tournilhac O, Gauchotte G, Lomazzi S, Chapiro E, Nguyen-Khac F, Chery C, Davi F, Hunault M, Houlgatte R, Rosenwald A, Delmer A, Meyre D, Béné MC, Thieblemont C, Lichter P, Ammerpohl O, Guéant JL; ICGC MMML-Seq Consortium; Guièze R, Martin-Subero JI, Cymbalista F, Feugier P, Siebert R, Stilgenbauer S. Molecular characterization of Richter syndrome identifies de novo diffuse large B-cell lymphomas with poor prognosis. Nat Commun. 2023, 14 (1): 309. doi: 10.1038/s41467-022-34642-6
  
• Caballero L R, Treudler R, Delaroque N, Simon J C, Kern K, Szardenings M. Peptide epitopes as biomarkers of soya sensitization in rBet v 1 immunotherapy of birch-related soya allergy. Clin Exp Allergy 2023, 53 (3): 316-326. doi: 10.1111/cea.14224
  
• Chilingaryan G, Izmailyan R, Grigoryan R, Shavina A, Arabyan E, Khachatryan H, Abelyan N, Matevosyan M, Harutyunyan V, Manukyan G, Hietel B, Shtro A, Danilenko D, Zakaryan H. Advanced virtual screening enables the discovery of a host-targeting and broad-spectrum antiviral agent. Antiviral Res 2023, 217, article 105681. doi: 10.1016/j.antiviral.2023.105681
  
• Ciulean I S, Fischer J, Quaiser A, Bach C, Abken H, Tretbar U S, Fricke S, Köhl U, Schmiedel D, Grunwald T. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol 2023, 14: 1290488. doi: 10.3389/fimmu.2023.1290488
  
• Dzhambazov B, Batsalova T, Merky P, Lange F, Holmdahl R. NIH/3T3 fibroplasts selectively activate T cells specific for posttranslationally modified collagen type II. Int J Mol Sci 2023, 24 (13), article: 10811. doi: 10.3390/ijms241310811
  
• Eberlein V, Ahrends M, Bayer L, Finkensieper J, Besecke J K, Mansuroglu Y, Standfest B, Lange F, Schopf S, Thoma M, Dressman J, Hesse C, Ulbert S, Grunwald T. Mucosal application of a low-energy electron inactivated respiratory syncytial virus vaccine shows protective efficacy in an animal model. Viruses 2023, 15 (9), article 1846. doi: 10.3390/v15091846
  
• Engel C, Wirkner K, Zeynalova S, Baber R, Binder H, Ceglarek U, Enzenbach C, Fuchs M, Hagendorff A, Henger S, Hinz A, Rauscher FG, Reusche M, Riedel-Heller SG, Röhr S, Sacher J, Sander C, Schroeter ML, Tarnok A, Treudler R, Villringer A, Wachter R, Witte AV, Thiery J, Scholz M, Loeffler M; LIFE-Adult-Study working group. Cohort Profile: The LIFE-adult-study. Int J Epidemiol 2023, 52 (1): E66 - E791. doi: 10.1093/ije/dyac114
  
• Feigl F F, Stahringer A, Peindl M, Dandekar G, Köhl U, Fricke S, Schmiedel D. Efficient redirection of NK cells by genetic modification with chemokine receptors CCR4 and CCR2B. Int J Mol Sci 2023, 24 (4), article 3129. doi: 10.3390/ijms24043129
  
• Finkensieper J, Mayerle F, Rentería-Solís Z, Fertey J, Makert G R, Lange F, Besecke J, Schopf S, Poremba A, König U, Standfest B, Thoma M, Daugschies A, Ulbert S. Apicomplexan parasites are attenuated by low energy electron irradiation in an automated microfluidic system and protect against infection with Toxoplasma gondii. Parasitol Res, 2023, 122(8): 1819-1832. doi: 10.1007/s00436-023-07880-w
  
• Freitag J S, Möser C, Belay R, Altattan B, Grasse N, Pothineni B K, Schnauß J, Smith D M. Integration of functional peptides into nucleic acid-based nanostructures. Nanoscale 2023, 15 (17): 7608-7624. doi: 10.1039/d2nr05429a
  
• Glaser M, Mollenkopf P, Prascevic D, Ferraz C, Käs J A, Schnauß J, Smith D M. Systematic altering of semiflexible DNA-based polymer networks via tunable crosslinking. Nanoscale. 2023, 15 (16): 7374-7383. doi: 10.1039/d2nr05615a
• Glatte B, Wenk K, Grahnert A, Friedrich M, Merz M, Vucinic V, Fischer L, Reiche K, Alb M, Hudecek M, Franz P, Fricke S, Platzbecker U, Koehl U, Sack U, Boldt A, Hauschildt S, Weiss R. Teclistamab impairs detection of BCMA CAR-T cells. Blood Adv 2023, 7 (15): 3842-3845. doi: 10.1182/bloodadvances.2023009714
• Han Y, Zhao J, Chao Z, Liang K, Zhang C, Jiang L, Jiao Z, Bai F, Tarnok A, You Z. Imaging flow cytometry using linear array spot excitation. Device 2023, 1 (6): 100124. doi: 10.1016/j.device.2023.100124
  
• He J, Shi Q, Chen Z, Zhang W, Lan P, Xu Q, Hu H, Chen Q, Jianzhong F, Jiang Y, Loh B W-C, Lepthin S, Zou Q, Zhang J, Yu Y, Hua X. Opposite evolution of pathogenicity driven by in vivo wzc and wcaJ mutations in ST11-KL64 carbapenem-resistant Klebsiella pneumoniae. Drug Resist Updat. 2023, 66: 100891. doi: 10.1016/j.drup.2022.100891
• Hilali N, Hangouët M, Bausells J, Kern K, Ramirez-Caballero L, Szardenings M, Polonschii Cristina, Mohammadi H, Amime A, Zine N, Errachid A. Fast impedimetric immunosensing of IgGs associated with peanut and hazelnut allergens. Biosens Bioelectron 2023, 242, article: 115612. doi: 10.1016/j.bios.2023.115612
  
• Hoen L, Pfeffer D, Schmidt J R, Kraft J, Hildebrand J, Kalkhof S. Hydration status of geriatric patients is associated with changes in plasma proteome, especially in proteins involved in coagulation. Nutrients 2023, 15 (17), article 3789. doi: 10.3390/nu15173789
  
• Issmail L, Ramsbeck D, Jäger C, Henning T, Kleinschmidt M, Buchholz M, Grunwald T. Identification and evaluation of a novel tribenzamide derivative as an inhibitor targeting the entry of the respiratory syncytial virus. Antiviral Res 2023, article 105547. doi: 10.1016/j.antiviral.2023.105547
  
• Kern K, Delaroque N, Boysen A, Puder M, Wendt R, Kölsch A, Ehrentreich-Förster E, Staerk K, Andersen T E, Andersen K, Lund L, Szardenings M. Glycosylation of bacterial antigens changes epitope patterns. Front Immunol 2023, 14: 1258136. doi: 10.3389/fimmu.2023.1258136
  
• Kiefer N, Nichterlein M, Reiß F, Runge M, Biermann U, Wieland T, Noll M, Kalkhof S. Eluates from façades at the beginning of their service time affect aquatic and sediment organisms. Sci Total Environ 2023, 906, article 167531. doi: 10.1016/j.scitotenv.2023.167531
  
• Kitte R, Rabel M, Geczy R, Park S, Fricke S, Koehl U, Tretbar SU. Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Mol Ther Methods Clin Dev, 2023, 31: 101139. doi: 10.1016/j.omtm.2023.101139
  
• Klinkmann G, Waterstradt K, Klammt S, Schnurr K, Schewe J-C, Wasserkort R, Mitzner S. Exploring albumin functionality assays: a pilot study on sepsis evaluation in intensive care medicine. Int J Mol Sci 2023, 24 (16), article 12551. doi: 10.3390/ijms241612551
  
• Klinkmann G, Wild T, Heskamp B, Doss F, Doss S, Milej M, Thiele L-M, Goudeva L, Blasczyk R, Reuter D, Altrichter J, Mitzner S. Extracorporeal therapy of sepsis by purified granulocyte concentrates—ex vivo circulation model. Artifical Organs 2023, 47 (7): 1151-1162. doi: 10.1111/aor.14507
  
• Lozada-Chávez I, Lozada-Chávez A N, Stadler P F, Prohaska S J. The genomes of complex multicellular organisms on Earth are characterized by high intron-richness. Revista mexicana de astronomía y astrofísica 2023, 55. doi: 10.22201/ia.14052059p.2023.55.14
  
• Massa C, Seliger B. Combination of multiple omics techniques for a personalized therapy or treatment selection. Front Immunol 2023, 14, article 1258013. doi: 10.3389/fimmu.2023.1258013
  
• Massa C, Wang Y, Marr N, Seliger B. Interferons and resistance mechanisms in tumors and pathogen-driven diseases - focus on the major histocompatibility complex (MHC) antigen processing pathway. Int J Mol Sci 2023, 24 (7), article 6736. doi: 10.3390/ijms24076736 
  
• Messer E K, Meyer A L, Klaeske K, Sieg F, Eifert S, Schmiedel D, Haunschild J, Jawad K, Saeed D, Hildebrandt L, Borger M A, Dieterlen M-T. The impact of obesity on T and NK cells after LVAD implantation. Obes Facts 2023, 16 (4): 364-373. doi: 10.1159/000530174
  
• Mollenkopf P, Prascevic D, Bayerl T M, Käs J A, Schnauß J. Heavy water induces bundling in entangled actin networks. RSC Adv 2023, 13 (35): 24795-24800. doi: 10.1039/d3ra03917j
  
• Mötzing M, Blüher M, Grunwald T, Hoffmann R. Immunological quantitation of the glycation site Lysine‐414 in serum albumin in human plasma samples by indirect ELISA using highly specific monoclonal antibodies. ChemBioChem 2023, online ahead of print, article e202300550. doi: 10.1002/cbic.202300550
• Mytzka N, Arbaciauskaite S, Sandetskaya N, Mattern K, Kuhlmeier D. A fully integrated duplex RT‑LAMP device for the detection of viral infections. Biomed Microdevices 2023, 25 (4), article 36. doi: 10.1007/s10544-023-00676-w 
  
• Nowak J, Bentele M, Kutle I, Zimmermann K, Lühmann J K, Steinemann D, Kloess S, Köhl U, Roßberg W, Ahmed A, Schaudien D, Neubert L, Kamp J-C, Kuehnel M P, Warnecke A, Schambach A, Morgan M. CAR-NK cells targeting HER1 (EGFR) show efficient anti-tumor activity against head and neck squamous cell carcinoma (HNSCC). Cancers (Basel) 2023, 15 (12), article 3169. doi: 10.3390/cancers15123169
  
• Quint I, Simantzik J, Kaiser L, Laufer S, Csuk R, Smith D, Kohl M, Deigner H-P. Ready-to-use nanopore platform for label-free small molecule quantification: ethanolamine as first example. Nanomedicine 2023, online aheas of print, article 102724. doi: 10.1016/j.nano.2023.102724
  
• Rade M, Böhlen S, Neuhaus V, Löffler D, Blumert C, Merz M, Köhl U, Dehmel S, Sewald K, Reiche K. A time-resolved meta-analysis of consensus gene expression profiles during human T-cell activation. Genome Biol. 2023, 24(1): 287. doi: 10.1186/s13059-023-03120-7
• Rauch-Wirth L, Renner A, Kaygisiz K, Zimmermann L, Rodríguez Alfonso AA, Schütz D, Wiese S, Ständker L, Weil T, Schmiedel D,  Münch J. Optimized peptide nanofibrils as efficient transduction enhancers for in vitro and ex vivo gene transfer. Front Immunol. 2023, 14:1270243. doi: 10.3389/fimmu.2023.1270243
  
• Rentschler S, Borgolte M, Filbert A, Laufer S, Deigner H-P. Highly efficient β-lactamase assay applying poly-dimethylacrylamide-based surface functionalization with β-lactam antibiotics and β-lactamase inhibitors. Lab Chip 2023, 23 (24): 5120-5130. doi: 10.1039/d3lc00682d
• Reus P, Guthmann H, Uhlig N, Agbaria M, Issmail L, Eberlein V, Nordling-David MM, Jbara-Agbaria D, Ciesek S, Bojkova D, Cinatl J, Burger-Kentischer A, Rupp S, Zaliani A, Grunwald T, Gribbon P, Kannt A, Golomb G. Drug repurposing for the treatment of COVID-19: Targeting nafamostat to the lungs by a liposomal delivery system. J Control Release 2023, 364: 654-671. doi: 10.1016/j.jconrel.2023.10.050
• Salti H, Kramer L, Nelz S-C, Lorenz M, Breitrück A, Hofrichter J, Frank M, Schulz K, Mitzner S, Wasserkort R. Decellularization of precision-cut kidney slices-application of physical and chemical methods. Biomed Mater 2023, 18 (2), article 025004. doi: 10.1088/1748-605X/acb02e
• Schäfer H, Subbarayan K, Massa C, Vaxevanis C, Mueller A, Seliger B. Correlation of the tumor escape phenotype with loss of PRELP expression in melanoma. J Transl Med 2023, 21, article 643. doi: 10.1186/s12967-023-04476-x
  
• Schimmelpfennig C, Rade M, Füssel S, Löffler D, Blumert C, Bertram C, Borkowetz A, Otto D J, Puppel S-H, Hönscheid P, Sommer U, Baretton G B, Köhl U, Wirth M, Thomas C, Horn F, Kreuz M, Reiche K. Characterization and evaluation of gene fusions as a measure of genetic instability and disease prognosis in prostate cancer. BMC Cancer 2023, 23, article 575. doi: 10.1186/s12885-023-11019-6
  
• Schmidt J R, Haupt J, Riemschneider S, Kämpf C, Löffler D, Blumert C, Reiche K, Koehl U, Kalkhof S, Lehmann J. Transcriptomic signatures reveal a shift towards an anti-inflammatory gene expression profile but also the induction of type I and type II interferon signaling networks through aryl hydrocarbon receptor activation in murine macrophages. Front Immunol 2023, 14: article number 1156493. doi: 10.3389/fimmu.2023.1156493
  
• Schulz J, Schilling E, Fabian C, Zenclussen A C, Stojanovska V, Claus C. Dissecting rubella placental infection in an In vitro trophoblast model. Int J Mol Sci, 2023, 24(9), article number 7894. doi: 10.3390/ijms24097894
  
• Szardenings M, Delaroque N, Kern K, Ramirez-Caballero L, Puder M, Ehrentreich-Förster E, Beige J, Zürner S, Popp G, Wolf J, Borte S. Detection of antibodies against endemic and SARS-CoV-2 coronaviruses with short peptide epitopes. Vaccines 2023, 11 (9), article 1403, doi: 10.3390/vaccines11091403
• Tan K, Jäger C, Geissler S, Schlenzig D, Buchholz M, Ramsbeck D. Synthesis and structure–activity relationships of pyrazole-based inhibitors of meprin α and β. J Enzyme Inhib Med Chem. 2023, 38 (1): 2165648. doi: 10.1080/14756366.2023.2165648
  
• Tanuchai B, Ji L, Schröder O, Gawol S J, Geissler A, Wahdan S F M, Buscot F, Kalkhof S, Schulze E-D, Noll M, Purahong W. Fate of a biodegradable plastic in forest soil: dominant tree species and forest types drive changes in microbial community assembly, influence the composition of plastisphere, and affect poly(butylene succinate-co-adipate) degradation. Sci Total Environ 2023, 873: article 162230. doi: 10.1016/j.scitotenv.2023.162230
  
• Thaher B A, Al-Masri I, Wahedy K, Morjan R, Aliwaini S, Al atter I M, Elmabhouh A A, Al Ibwaini A K, Alkhaldi S L, Qeshta B, Jacob C, Deigner H-P. Synthesis and bioassay of 3-Aryl -1-(pyridin-4-yl)benzo[4,5]imidazo[1,2-d][1,2,4]- triazin-4(3H)-ones as anti-cancer agents. Naunyn Schmiedebergs Arch Pharmacol. 2023, 396(8): 1797-1810. doi: 10.1007/s00210-023-02433-5
  
• Tong L, Kremer V, Neo SY, Liu Y, Chen Y, Wagner AK, Yang Y, Chen Z, Seitz C, Tobin NP, Ligtenberg MA, Alici E, Chen X, Haglund F, Seliger B, Harmenberg U, Colón E, Plogell AS, Liu LL, Lundqvist A. Renal cell carcinoma escapes NK cell-mediated immune surveillance through the downregulation of DNAM-1. Cancer Commun (Lond.) 2023, 43 (7): 855-859. doi: 10.1002/cac2.12446  
• Vaxevanis C K, Bauer M, Subbarayan K, Friedrich M, Massa C, Biehl K, Al-Ali H K, Wickenhauser C, Seliger B. Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy. OncoImmunology 2023, 12 (1), article 2152998. doi: 10.1080/2162402X.2022.2152998
  
• Vogelsberg E, Moors M, Sorokina A S, Ryndyk D A, Schmitz S, Freitag J S, Subbotina A V, Heine T, Abel B, Monakhov K Y. Solution-processed formation of DNA-origami-supported polyoxometalate multi-level Switches with countercation-controlled conductance tunability. Chem Mater 2023, 35 (14). doi: 10.1021/acs.chemmater.3c00776
  
• von Auw N, Serfling R, Kitte R, Hilger N, Zhang C, Gebhardt C, Duenkel A, Franz P, Koehl U, Fricke S, Tretbar U S. Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality. Sci Rep. 2023, 13 (1): 18160. doi: 10.1038/s41598-023-45197-x
• Wang N, Lei T, Zhu Y, Li Y, Cai H, Zhang P, Leptihn S, Zhou J, Ke H, Gao B, Feng Y, Hua X, Qu T. Characterization of two novel VIM-type metallo-β-lactamases, VIM-84 and VIM-85, associated with the spread of IncP-2 megaplasmids in Pseudomonas aeruginosa. Microbiol Spectr 2023, 11 (5), article e0154423. doi: 10.1128/spectrum.01544-23
• Wang Y, He J, Sun L, Jiang Y, Hu L, Leptihn S, Zhu P, Fu X, Yu Y, Hua X. IS26 mediated blaCTX-M-65 amplification in Escherichia coli increase the antibiotic resistance to cephalosporin in vivo. J Glob Antimicrob Resist 2023, 35: 202-209. doi: 10.1016/j.jgar.2023.09.018
  
• Wang Y, Jasinski-Bergner S, Wickenhauser C, Seliger B. Cancer immunology: immune escape of tumors - expression and regulation of HLA class I molecules and its role in immunotherapies. Adv Anat Pathol 2023, 30 (3): 148-159. doi: 10.1097/PAP.0000000000000389
  
• Weiß R, Issmail L, Rockstroh A, Grunwald T, Fertey J, Ulbert S. Immunization with different recombinant West Nile virus envelope proteins induces varying levels of serological cross-reactivity and protection from infection. Front Cell Infect Microbiol, 2023, 13: 1279147. doi: 10.3389/fcimb.2023.1279147
  
• Zhang X, Greiser S, Roy U, Lange F, Gorkum R v, Fournelle M, Speicher D, Tretbar S, Melzer A, Landgraf L. Evaluation of a developed MRI-guided focused ultrasound system in 7 T small animal MRI and proof-of-concept in a prostate cancer xenograft model to improve radiation therapy. Cells 2023, 12 (3), article 481, doi: 10.3390/cells12030481

• Blache U, Kebbel K, Quaiser A, Popp G, Franz P, Dünkel A, Thoma M, König N, Platzbecker U, Schmiedeknecht G, Fricke S, Köhl U. Technologien und Lösungsansätze für die effiziente Herstellung von Zelltherapeutika für die CAR-Immuntherapie. In: Fehse B et al.: Gen- und Zelltherapie 2.023 – Forschung, klinische Anwendung und Gesellschaft. Springer, 2024, Seite 123-137. doi: 10.1007/978-3-662-67908-1_8 
  
• Klinkmann G, Koball S, Reuter D A, Mitzner S. Hemoperfusion with CytoSorb®: current knowledge on patient selection, timing, and dosing. In: Bellemo, R et al.: Adsorption: the new frontier in extracorporeal blood purification. Karger, 2023, Seite 17-24. doi: 10.1159/000527774

• Andreola F, Agarwal B, Mitzner S et al. THU-355 - pathophysiological biomarkers associated with resolution of ACLF in patients treated with the liver dialysis device, DIALIVE. J Hepatol 2023, 78, Suppl. 1, S220-S222. doi: 10.1016/S0168-8278(23)00768-7
• Jöckel L, Kläs M, Popp G, Hilger N, Fricke S. Uncertainty wrapper in the medical domain: establishing transparent uncertainty quantification for opaque machine learning models in practice. arXiv:2311.05245. doi: 10.48550/arXiv.2311.05245
  
• Kämpf C, Scholz A, Kreuz M, Reiche K. From research to regulated software. Vortrag auf deRSE23 - conference for research software engineering in Germany (3. : 2023 : Paderborn). doi: 10.5281/zenodo.7751723
• Kebbel K. Zell- und Gentherapie - Wie transferiert man Prozesse sicher und effektiv? Pharm. Ind. 2023, 85 (11): 1055–1060
  
• Kürzel S, Blaudszun AR, Stahl L, Herbst R, Kroschinsky F, Birkmann J, Hänel A, Schaefer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M, Fricke S*, Hänel M.* Correction: Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow‑up of 14.4 years. J Cancer Res Clin Oncol 2023, 149: 929-931. doi: 10.1007/s00432-022-04324-3
• Lehmann J, Szardenings M, Schillberg S, Eisner P. Diagnostische Tools zum Nachweis von Allergenen in Lebensmitteln. Der Lebensmittelbrief 2023, Mai/Juni
  
• Mushunuri R V, Choschzick M, Braumann U-D, Hess J. An ensemble approach for histopathological classification of vulvar cancer. Proceedings 2023, 12471, SPIE Medical Imaging, 2023, San Diego. doi: 10.1117/12.2653858
  
• Quaiser A, Köhl U. Medizinforschung: Koordination und Kooperation gefragt - Deutschlands Beitrag zur klinischen Forschung: Forschungskultur und politischer Gestaltungswille. Frankfurter Forum 2023, 27:30-37
  
• Schmiedel D, Schmid T, Tretbar S, Fricke S. Forschung für die Praxis. Transkript Laborwelt 2023, 29 (3): Seite 76-79
• Schönfelder J, Elkmann N, Kuhlmeier D. RoboLab - autonome Gesundheitskioske der Zukunft. Management & Krankenhaus 2023, 3: 32. 154007 (management-krankenhaus.de)
• Seliger B. Tumor immunology meets oncology (TIMO) XVI, July 07–09 2022 in Halle/Saale, Germany. Cancer Immunology, Immunotherapy 2023, online ahead of print. Cancer Immunol, Immunotherapy (2023) 72: 3125-313. doi: 10.1007/s00262-023-03468-6
  
• Suerth JD, Morgan MA, Kloess S, Heckl D, Neudörfl C, Falk CS, Koehl U, Schambach A. Correction to: Efficient generation of gene-modified human natural killer cells via alpharetroviral vectors. J Mol Med (Berl) 2023, Dec, 102: 143-145. doi: 10.1007/s00109-023-02404-6
  
• Tárnok A. Counting rare earth metals. Cytometry Part A, 2023, 103 (8): 618, doi: 10.1002/cyto.a.24784
  
• Tárnok A. The first tissue OMIP is out and alternative modalities to analyze single cells and particles. Cytometry Part A, 2023, 103 (3): 175 - 176. doi: 10.1002/cyto.a.24724
• Wijewardana V, Ulbert S, Cattoli G. Irradiation technologies for vaccine development. Front Immunol 2023, 139, article number 1075335. doi: 10.3389/fimmu.2022.1075335
  

• Ammar D, Awigena-Cook J, Moukheiber C, Arnould S, Cullmann K, Choudhary R, Schapitz I, Prósper F, Quintarelli C, Buchholz C, Ivics Z, Müller M, Köhl U, Hudecek M, Sanges C, Negre H, Franz P. Approaching regulatory challenges for the development of new engineered T cell therapies in Europe. 5th European CAR T-cell Meeting, 9.-11.2.2023, Rotterdam, The Netherlands
• Blache U, Tretbar S, Franz P, Schmiedel D, Koehl U, Fricke S. Case-based lecture: Alternative cell sources for adoptive immunotherapy. ESH - European School of Hematology, 2nd How I Manage CAR-T Therapies and Bispecific Antibodies for my Patients, SESSION I – Non-hodgkin lymphoma (NHL), 29.9.2023, Berlin
• Blaudszun AR. Induction of Graft-versus-Host disease in mouse models. SaxoCell-Sparkmeeting, 11.5.2023
• Bräuning S, Schiefer D, Möser C, Greiser S, Köhl U, Fricke S, Blache U, Tretbar S. Evaluation of Transient aFAP CAR-T Cell Activity Against Activated Fibroblasts Using Incucyte Cytotoxicicty Assays. Incucyte User Group Meeting, 14.-15.6.2023, Heidelberg
• Bräuning S, Schiefer D, Möser C, Greiser S, Köhl U, Fricke S, Blache U, Tretbar S. mRNA Technology for the Development of CAR-T Cells Targeting Fibrotic Diseases. ICLE 2023, 12.-14.9.2023, München
• Ciulean IS, Fischer J, Possardt E, Köhl U, Grunwald T. Development of a 3-dimensional head and neck cancer cell culture model for the assessment of NK cell-based therapies. Workshop Advanced Cell Culture Technologies, 17.3.2023, Vienna, Austria
• Ciulean IS, Fischer J, Tretbar S, Quaiser A, Fricke S, Köhl U, Schmiedel D, Grunwald T. The potential of CAR-NK cells as targeted immunotherapy for head and neck squamous cell carcinoma. The 20th Meeting of the Society for Natural Immunity (SNI) - NK2023, 26.-29.9.2023, Oslo, Norway
• Ciulean IS, Uhlig J, Eichenberg T, Fischer J, Albers M, Breunig C, Schmollinger J, Pahl J, Fucek I, Bach C, Franz P, Dünkel A, Fricke S, Grunwald T, Köhl U, Koch J. Redirecting NK cell cytotoxicity by innate cell engagers: a differentiated and innovative approach compared to CAR-NK cells. J Immunother Cancer 2023, 11 (Suppl 1): 376-376. doi: 10.1136/jitc-2023-SITC2023.0329
• Ciulean IS, Uhlig J, Eichenberg T, Fischer J, Albers M, Breunig C, Schmollinger J, Pahl J, Fucek I, Bach C, Franz P, Dünkel A, Fricke S, Grunwald T, Köhl U, Koch J. Redirecting NK cell cytotoxicity by innate cell engagers: a differentiated and innovative approach compared to CAR-NK cells. 38th Annual Meeting  of the Society of Immunotherapy of Cancer- SITC 2023, 1.-5.11.2023, San Diego, USA
• Delaroque N, Kern K, Müller C, Lehmann J, Szardenings M. Epitope Fingerprinting for the Identification of Antigens. PEGS Europe, 14.-16.11.2023, Lisbon, Portugal
• Eberlein V, Ahrends M, Bayer L, Finkensieper J, Mansuroglu Y, Rosencrantz S, Standfest B, Lange F, Schopf S, Dressman J, Thoma M, Hesse C, Ulbert S, Grunwald T. Protective efficacy of a mucosal delivered inactivated whole virus RSV vaccine in mice. CIMD Summer School 2023, 12.-15.9.2023, Leipzig
• Eberlein V, Ahrends M, Bayer L, Finkensieper J, Mansuroglu Y, Rosencrantz S, Standfest B, Lange F, Schopf S, Dressman J, Thoma M, Hesse C, Ulbert S, Grunwald T. Protective efficacy of a mucosal delivered inactivated whole virus RSV vaccine in mice. A Global Conference on Novel RSV Preventive and Therapeutic Interventions RSVVW'23, 22.-24.2.2023, Lisbon, Portugal
• Eberlein V, Ahrends M, Bayer L, Finkensieper J, Mansuroglu Y, Rosencrantz S, Standfest B, Lange F, Schopf S, Dressman J, Thoma M, Hesse C, Ulbert S, Grunwald T. Protective efficacy of a mucosal delivered inactivated whole virus RSV vaccine in mice. DgfI SPRING SCHOOL ON IMMUNOLOGY 2023, 6.-10.3.2023, Ettal
• Feigl F, Stahringer A, Peindl M, Dandekar G, Koehl U, Fricke S, Schmiedel D. Efficient Redirection of NK Cells by Genetic Modification with Chemokine Receptors CCR4 and CCR2B. NK2023, 26.-29.9.23, Oslo, Norway
• Fertey J, Issmail L, Finkensieper J, Thoma M,König U, Grunwald T, Ulbert S. Low energy electron irradiation efficiently inactivates various viruses in liquids for vaccine production processes. European Congress of Virology, 4.-7.5.2023, Gdansk, Poland
• Finkensieper J, Issmail L, Fertey J, Makert G, Schopf S, Standfest B, Thoma M, Grunwald T, Ulbert S. Toxoplasma gondii attenuated by low-energy-electron irradiation induces protective immune responses. International Symposium on Zoonoses Research, 9.-11.10.2023, Berlin
• Franz P. Cell & Gene Therapy Development at Fraunhofer IZI. Symposium »Automatisierte Dezentrale ATMP Produktionstechnologien – ADAPT«,  Fraunhofer-Institut für Produktionstechnik und Automatisierung IPA, 1.12.2023, Stuttgart
• Fricke S, Hänel M. Paradigmenwechsel in der Hämatologie/Onkologie. 2. Ideenwerkstatt Technische Universität Chemnitz, 12.12.2023, Chemnitz
• Fricke S, Warncke P. Immuntherapie in der Hämatologie: Die Zukunft der Krebsmedizin? Onkologie im Dialog, 16.9.2023, Lichtenstein
• Fricke S. Cytiva’s ISCT Corporate Session on Accelerating the path to new cell and gene therapies on 01/06/2023 Roundtable “Overcoming challenges and opportunities to advance new cell therapies". ISCT Paris, 31.5.-3.6.2023, Paris, France
• Fricke S. EXPERT FORUM 2023 CAR T: AN ERA OF INNOVATION IN HAEMATOLOGY. EXPERT FORUM 2023 CAR T: AN ERA OF INNOVATION IN HAEMATOLOGY, 10.-11.3.2023, London, UK
  
• Fricke S. Aktuelle immuntherapeutische Therapieansätze - Immuntherapie in der Hämatologie: Die Zukunft der Krebsmedizin? 9. Bundesweiter Erfahrungsaustausch zu Lotsensystemen in Deutschland und Refresher-Kurs für Onkolotsen, Sächsische Krebsgesellschaft, 10.11.2023, online 
• Fricke S. CAR T manufacturing. Expert-Circle, Update Therapieoptionen für hämatologische Neoplasien und solide Tumoren, 3.5.2023, Chemnitz
• Fricke S. Entwicklung von CAR– T–Zell–Therapien in der Onkologie. MSGO-Frühjahrskolloquium für Urologie, Onkologie und Palliativmedizin, 21.4.2023, Leipzig
• Fricke S. Immuntherapie – Quo vadis? Molekulare Diagnostik und Immuntherapie in Hämatologie & Onkologie, 29.4.2023, Lichtenwalde
• Fricke S. Innovations in cell and gene therapy production. 2. Ideenwerkstatt Technische Universität Chemnitz, 12.12.2023, Chemnitz
• Fricke S. Predicting response to CAR T-Cell Therapy: biomarkers and prognostic factors in r/r large B-cell lymphoma. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Fricke S. Therapiebegleitende psychoonkologische Behandlung von (Palliativ-)patienten: theoretische und praktische Grundlagen der Diagnostik und Behandlung bei Angsterkrankungen. MSGO-Herbstkolloquium für Urologie, Onkologie und Palliativmedizin, 11.10.2023, Leipzig
• Fricke S. Wissenschaftliche Leitung: CLL Focus Event: Time-limited combination therapies in CLL 1L – how to treat in 2023, Fachbereich Medizin Hämatologie. Klinikum Chemnitz, Referent: Prof. Dr. med. Paolo Ghia Milano, 31.5.2023, online
• Fricke S. Wissenschaftliche Leitung: Fokus Hämatologie, Moderne Immuntherapien beim Multiplen Myelom – praktische Erfahrungen und Handling. Klinikum Chemnitz, Referent: PD Dr. Merz UKL Leipzig, 18.10.2023, online
• Fricke S. Wissenschaftliche Leitung: Fokus Hämatologie: Therapieentwicklungen und Herausforderungen in der Behandlung des Multiplen Myeloms. Klinikum Chemnitz, Referent: Prof. Dr. Munder Mainz, 21.6.2023, online
• Funke N, Graf A, Hild OR, Schönfelder J, Scholles M. Influence of different ketones on the spectra of a MEMS FAIMS-chip. MikroSystemTechnik Kongress 2023, 23.-25.10.2023, Dresden
• Gebhardt C, von Auw N, Rabel M, Zhang A, Hilger N, Kitte R, Serfling R, Franz P, Fricke S, Köhl U, Tretbar U. CARcoon - scaling up mRNA CAR-T cell manufacturing with the Cocoon®platform -a work-in-progress master thesis. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Große F P, Schmidt M, Löffler D, Rade M, Blumert C, Löffler-Wirth H, Binder H, Stubenvoll A, Schultz C, Stiller M, Simon J C, Ziemer M, Reiche K, Kunz M. Cell-cell communication in melanoma and further steps towards the risk assessment of immunotherapy target combinations with large-scale data sources. ScaDS.AI General Assembly, 14.12.2023, Leipzig
• Herrmann A, Hahn F, Wangen C, Häge S, Gege C, Schreieck A, Peelen E, Uhlig N, Eberlein V, Issmail L, Grunwald T, Marschall M, Muehler A, Vitt D, Kohlhof H. Preclinical development of optimized DHODH inhibitors as broad-spectrum antivirals for the treatment of respiratory virus infections. 32. Jahreskonferenz der Gesellschaft für Virologie e. V., 28.-31.3.2023, Ulm
• Hoen L, Kraft J, Hildebrand J, Kalkhof S. Dehydratation – Nachweismethodik, Kohortenerfassung, Ursachenkorrelation und Präventionsstrategien. Symposium des Gesundheitsjahr der Technologieallianz Oberfranken (TAO), 14.2.2023, Hof
• Hoffmann A, Riemschneider S, Klose K, Antoniadou O, Bruns V, Kreuz M, Kosinska A, Thiele F, Wiegand M, Protzer U, Lehmann J. Pathohistological evaluation to exclude immunotoxic effects of the TherVacB vaccine in liver tissue. Results from an immunotoxicity GLP study using a transgenic AAV-HBV mouse model. 20th European Society of Toxicologic Pathology Congress, 26.-29.9.2023, Basel, Switzerland
• Issmail L, Ramsbeck D, Jäger C, Henning T, Kleinschmidt M, Buchholz M, Grunwald T. Identification of a novel benzamide derivative as a small-molecule inhibitor targeting the entry of the respiratory syncytial virus. A Global Conference on Novel RSV Preventive and Therapeutic Interventions RSVVW'23, 22.-24.2.2023, Lisbon, Portugal
• Issmail L, Ramsbeck D, Jäger C, Henning T, Kleinschmidt M, Buchholz M, Grunwald T. Identification of a novel benzamide derivative as a small-molecule inhibitor targeting the entry of the respiratory syncytial virus. 32. Jahreskonferenz der Gesellschaft für Virologie e. V., 28.-31.3.2023, Ulm
• Kalkhof S. Personalisierte Behandlung von Brüchen und Wunden durch Scaffolds aus dem 3D Drucker. Gesundheitskongress des Gesundheitsjahr der Technologieallianz Oberfranken (TAO), 20.10.2023, Hof
• Kistenmacher A-K, Uhlig J, Köhl U, Fricke S, Franz P, Dünkel A, Blache U. Improving cell culture conditions for GMP-compatible NK cell expansion. NK2023, 26.-29.9.2023, Oslo, Norway
• Kistenmacher A-K, Uhlig J, Köhl U, Fricke S, Franz P, Dünkel A, Blache U. Improving cell culture conditions for GMP-compatible NK cell expansion. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Kitte R, Rabel M, Fricke S, Koehl U, Tretbar S. Efficient transient CAR T cell therapy is a matter of mRNA and delivery method. International Advanced Drug Delivery Symposium, 25.-26.5.2023, Hsinchu, Taiwan
• Kitte R, Rabel M, Fricke S, Koehl U, Tretbar S. Engineering chimeric antigen receptor (CAR) T cells via mRNA-LNPs for cancer immunotherapy. International mRNA Health Conference, 31.10.-2.11.2023, Berlin
• Kitte R, Warncke P, Rabel M, Hänel M, Fricke S, Koehl U, Tretbar S. Lipid nanoparticle (LNP) mediated mRNA delivery for transient CAR T cell generation. DPhG-Jahrestagung 2023 / Annual meeting, 7.10.2023, Tübingen
• Kitte R. Lipid nanoparticle (LNP)-mediated mRNA delivery for transient CAR T cell engineering. Accelerating Innovation Across Cell Therapies, Viral Vectors, Oligonucleotides and mRNA Delivery Workshop, 13.11.2023, virtual
• Köhl U. Academic needs for HE: technical perspective. 49. Annual Meeting of EBMT - Multi-Stakeholder Forum, 23.-26.04.2023, Paris, France
• Köhl U. Academic vector production. 7th French International Symposium "CAR T Day", 6.-8.9.2023, Lille, France
• Köhl U. Advanced concepts for CAR-T manufacturing - overview. 5. Eurpean CAR T-cell-Meeting, 9.-11.2.2023, Rotterdam, The Netherlands
• Köhl U. Fortschritte in der Zelltherapie: Wird Krebs heilbar? Symposium des Verein Hilfe für Krebskranke Kinder e. V., 6.10.2023, Frankfurt/Main
• Köhl U. From CAR T to CAR NK cells: Pushing the boundaries in cancer treatment and beyond. NK2023: 20th Meeting of the Society for Natural Immunity (SNI), 26.-28.9.2023, Oslo, Norway
• Köhl U. Gene therapy for pushing the boundaries in cancer treatment. Tumor immunology meets infectious diseases (TIMID) Symposium, 14.7.2023, Brandenburg an der Havel
• Köhl U. Innovative Zell-/ Gentherapeutika: geteilte Erfahrungen aus der Immunonkologie. Deutscher Rheumatologie-Kongress (DGRh), 31.8.-1.9.2023, Leipzig
• Köhl U. Lebende Krebsmedikamente für Alle - technologische Souveränität durch automatische Pharmaproduktion. PharmaForum, 16.2.2023, Mainz
• Köhl U. Manufacturing of CAR effector cells: pushing the boundaries in cancer treatment and immune mediated diseases. 11th International Meeting Stammzellnetzwerk.NRW, 15.-17.5.2023, Aachen
• Köhl U. Neue Optionen bei CAR-Effektorzellen. IGLD-Jahrestagung, 23.-24.3.2023, Frankfurt/Main
• Köhl U. Robotization in T cell manufacturing. 7. Zelltherapie-Symposium, 3.-4.11.2023, Heidelberg
• Köhl U. What could be the future of genetically modified lymphocytes in MDS. 17. Intern. Congress of Myelodysplastic Syndromes (MDS), 4.-6.5.2023, Marseille, France
• Köhl U. Zelltherapeutika der Zukunft. Pharmcon-Kongress, 5.-6.6.2023, Meran, Italy
• Körtge A, Krüsemann H, Aldarwish S, Wasserkort R, Hinz S, Mitzner S. Development of a simple organ perfusion setup for investigasting the effect of therapeutic methods on marginal organs. 49th ESAO - IFAO Annual Congress (European Society of Artificial Organs), 29.8.-1.9.2023, Bergamo, Italy
• Kottwitz AK, Piechotta A, Parthier C, Linnert M, Schrempel S, Roßner S, Morawski M, Rahfeld JU, Schilling S. Structural and functional Analysis of novel 3-Nitrotyrosine Aβ-specific Antibodies. Alzheimer's Association International Conference, 16.-20.7.2023, Amsterdam, The Netherlands
• Lehmann S, Oberbach A, Schlichting N. Analyse und Optimierung von digitalen Ökosystemen in der Patientenversorgung. Life Science Forum Sachsen, 27.9.2023, Hoyerswerda
• Lischer C, Tretbar S, Kitte R, Schmiedel D, Hamann A, Völkl S, Bruns H, Mougiakakos M, Vera J. Single-molecule Genome Sequencing Elucidates Genomic Variants After Viral Transduction in CAR-T Cells. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Löffler D, Große F, Grieb N, Rade M, Blumert C, Fischer L, Reiche K, Merz M. Spatial transcriptomics in bone marrow biopsies from patients with multiple myeloma. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Lohße S, Schönfelder J, Gjurova B, Bangen LM, Smith DM. Gas chromatography-ion mobility spectrometry (GC-IMS) investigations; volatilome of healthy and cancerous prostate cells under normoxic and hypoxic growth conditions. International Conference on Ion Mobility Spectrometry, 21.-25.8.2023, Maastricht, The Netherlands
  
• Müller C, Koehl U, Lehmann J. In-vitro validation of Glypican-1 as a novel potential target for antibody- or CAR-based therapies of triple-negative breast cancer (TNBC). Festival of Biologics; 10.-12.10.2023, Basel, Switzerland
• Müller C, Przybylski-Wartner S, Mestermann K, Prommersberger S, Beckmann J, Hudecek H, Koehl U, Lehmann J. Regulatory approval study for a novel ROR1 CAR-T cell product against hematologic and solid malignancies. Festival of Biologics; 10.-12.10.2023, Basel, Switzerland
• Nelz C, Lück E, Doss S, Sauer M, Hofrichter J. Evaluation of the in vitro compatibility of plasma and hiPSC-derived microvascular endothelial cells. 2nd Belgian Brain Barriers Symposium, 14.-15.11.2023, Leuven, Belgium
• Nelz C, Lück E, Doss S, Sauer M, Hofrichter J. Evaluation of the in vitro compatibility of plasma and hiPSC-derived microvascular endothelial cells. Stammzellnetzwerk.NRW – 11th International Meeting 2023, 16.-17.5.2023, Aachen
• Nichterlein M, Kiefer N, Müller D, Ciok M, Noll M, Kalkhof S. Degradation, leaching and ecotoxicological behavior of encapsulated and non-encapsulated biocides from building façades. SETAC Europe 33rd Annual Meeting, 30.4.-4.5.2023, Dublin, Ireland
• Oberbach A, Lehmann S, Schlichtung N, Volkwein M, Wiebelitz L, Israel M, Ochs M, Wickenkamp A. Identifizierung von Datenbrüchen in Patientenpfaden zur  Erzielung von Interoperabilität im Gesundheitswesen. ZDD® Stakeholder Workshop, 7.7.23, Potsdam
• Oberbach A, Lehmann S, Schlichtung N, Volkwein M, Wiebelitz L, Israel M, Schöning S, Reul K, Ochs M, Wickenkamp A, Gorch J. Datenbrüche in Patientenpfaden zu identifizieren ist die Grundlage, um Interoperabilität im Gesundheitswesen zu erzielen. DMEA, 25.-27.4.2023, Berlin
• Renner A, Stahringer A, Fricke S, Köhl U, Schmiedel D. Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated natural killer cells. NK2023, 26.-29.9.2023, Oslo, Norway
• Renner A. Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Roßbach L, Franz P, Dünkel A, Fricke S, Adlkofer K, Deblandre G. “LIVE” Cell shipment: a forward-looking transport option for “cryo-sensitive” cell-based therapies. Cytotherapy 2023, 25 (6), S7-S283. doi: 10.1016/S1465-3249(23)00158-5
• Roßbach L, Franz P, Dünkel A, Fricke S, Adlkofer K, Deblandre G. “Live” cell shipment in the cellbox portable incubator - a forward-looking transport option for "cryo-sensitive" cell-based therapies. ISCT 2023, 31.5.-3.6.2023, Paris, France
• Roth K, Loeffler D, Blumert C, Scholz A, Reiche K, Schiefer D, Hilger N, Tretbar S, Köhl U, Fricke S, Blache U. Ex vivo Modification of Hematopoietic Cell Transplants in GvHD Prevention: Revealing the Mechanism of Action of the Anti-Human CD4 Antibody MAX.16H5 for Induction of Immune Tolerance. 20th CIMT Annual Meeting, 3.-5.5.2023, Mainz
• Ruppel K, Fricke S, Köhl U, Schmiedel U. Increasing the persistence and efficiency of Chimeric Antigen Receptor - NK cells. ICLE 2023, 12.-14.9.2023, München
• Ruppel K, Fricke S, Köhl U, Schmiedel U. Increasing the persistence and efficiency of Chimeric Antigen Receptor - NK cells. NK2023, 26.-29.9.2023, Oslo, Norway
• Ruppel K, Schmiedel D. Anti CD4 Chimeric Antigen Receptor - NK cells To target T cell malignancies. TIMO 2023, 20.-22.4.2023, Halle (Saale)
• Schenk M, Rahfeld JU, Linnert M, Schilling S, Stubbs MT. Development of antibody 5G4 against pathological α-synuclein for treatment of Parkinson’s disease. DLS-CCP4 Data Collection and Structure Solution Workshop, 27.11.-5.12.23, Harwell, UK
• Schindler K, Fricke S, Köhl U, Schmiedel D. Empowering NK cell immunotherapy against Multiple Myeloma using combined engineering strategies. NK2023, 26.-29.9.2023, Oslo, Norway
• Schindler K. Empowering NK cell immunotherapy in Multiple Myeloma using combined engineering strategies. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Schmidt J, Wiltzsch V, Dias DB, Adamowicz K, Lio CT, Arend L, Lehmann J, Lingner T, Tsoy O, Laske T, Poh P,  Baumbach Jan, Kalkhof S. Plasma proteomics to reveal liquid biopsy-accessible indicative biomarkers for impaired bone fracture healing in type 2 diabetes mellitus using personalized 3D-printed scaffolds. DGBM, 14-16.9.2023, Jena
• Schmidt J, Wiltzsch V, Dias DB, Adamowicz K, Lio CT, Arend L, Lehmann J, Lingner T, Tsoy O, Laske T, Poh P, Baumbach J, Kalkhof S. Integrative tissue and plasma proteomics revealed liquid biopsy-accessible indicative biomarkers for impaired bone fracture healing in type 2 diabetes mellitus. TERMIS-EU, 28.-31.3.2023, Manchester, UK
• Scholz A, Joas M, Ewald J, Reiche K. SaxoCellOmics Galaxy Server. SaxoCell Consortiumsmeeting, 11.- 12.9.2023
• Serfling R, Kitte R, von Auw N, Bräuning S, Fricke S, Köhl U, Tretbar S. Accelerating mRNA therapeutics in cancer immunotherapy: designing efficient CAR-T cell constructs. International mRNA Health Conference, 31.10.-2.11.2023, Berlin
• Serfling R, Kitte R, von Auw N, Bräuning S, Fricke S, Köhl U, Tretbar S. Unleashing the potential of mRNA therapeutics: enhancing T Cell immunotherapy through CAR mRNA optimization. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Szardenings M, Delaroque N, Kern K, Puder M, Ehrentreich-Förster E, Wendt R, Boysen A, Zahle A. Similarity of the immune response in different species at epitope level in vaccine development. PepTalk, 16.-20.1.2023, San Diego, USA
• Szardenings M. Personalized immune diagnostics: mapping of the epitome. PIE 2024, 30.3.-2.4.2023, Reisensburg
• Töllner P, Hofrichter J, Krüsemann H, Jenßen B, Seitz H. Additive manufacturing of a miniaturized ceramic implant for animal studies on the treatment Alzheimer’s disease. Trans. AMMM 2023, 5 (1), Suppl. 1 , article 791. doi: 10.18416/AMMM.2023.2309791
• Tretbar S. Biologische Einblicke in die Entwicklung von mRNA-basierten Impfstoffen und Zell- und Gentherapien. Spotlights der Mikro- und Nanotechnologie, 10.1.2023, online
• Tretbar S. Development and potential of mRNA-based cell and gene therapies. KIT Webinar, 15.2.2023, online
• Tretbar S. Development and potential of mRNA-based cell therapies. Fraunhofer IESE Hackathon, 27.10.2023, online
• Tretbar S. EduTalk: mRNA-LNP technology for safe CAR cell therapy. Sartorius, 15.11.2023, online
• Tretbar S. Immune cell engineering for cancer retargeting. Biomaterials & Bioresponse Symposium, 23.11.2023, Halle (Saale)
• Tretbar S. mRNA-LNP technology for safe CAR cell therapy. Cytiva User Day, 27.9.2023, Leipzig
• Tretbar S. mRNA-LNP technology for safe CAR cell therapy. University of Coimbra Webinar, 18.10.2023, online
• Tretbar S. mRNA-LNP technology for safe CAR cell therapy. PNI Symposium, 7.12.2023, online
• Tretbar S. Non-viral gene transfer for cancer immunotherapy. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Tretbar S. Rise of new and enabling technologies for CGT success. Bioprocessing Summit, 11.5.2023, Berlin
• Tretbar S. Transient CAR-T cell therapy using TheraPeak T-Vivo medium. ASGCT, 18.5.2023, Los Angelos, USA
• Uhlig N, Donner A-K, Fertey J, Rau S, Siebert J, Trendowicz A, Kläs M, Jedlitschka A, Hettrich C, Kuhlmeier D, Ulbert S, Grunwald T. Next-generation virus testing for on-demand diagnosis and outbreak containment. CIMD Summer School 2023, 12.-15.9.2023, Leipzig
• Ulbert S. Low energy electron irradiation: a novel method in pharmaceutical production processes. PharmaLab, 21.-22.11.2023, Düsseldorf
• von Auw N, Serfling R, Kitte R, Hilger N, Zhang C, Gebhardt C, Dünkel A, Franz P, Köhl U, Fricke S, Tretbar S. How to improve mRNA-based CAR-T cell generation and functionality? A lab-scale comparison. Leipzig Immune ONcology (LION) Conference, 8.-9.11.2023, Leipzig
• Weirauch U, Alb M, Weiß R, Löffler D, Kopfnagel V, Blumert C, Düll J, Scheller L, Boldt A, Vucinic V, Platzbecker U, Köhl U, Hudecek M, Reiche K. In-depth characterization of the immune microenvironment of patients undergoing CAR T cell therapy. ISCT, 31.5.-3.6.3023, Paris, France
• Weirauch U, Alb M, Weiß R, Löffler D, Kopfnagel V, Blumert C, Düll J, Scheller L, Boldt A, Vucinic V, Platzbecker U, Köhl U, Hudecek M, Reiche K. In-depth characterization of the immune microenvironment of patients undergoing CAR T cell therapy. 21st International AEK Cancer Congress, 15.-17.2.2023, Kassel
• Weirauch U, Alb M, Weiß R, Löffler D, Kopfnagel V, Blumert C, Düll J, Scheller L, Boldt A, Vucinic V, Platzbecker U, Köhl U, Hudecek M, Reiche K. In-depth characterization of the immune microenvironment of patients undergoing CAR T cell therapy. EBMT-EHA 5th European CAR T-cell Meeting, 9.-11.2.2023, Rotterdam, The Netherlands
• Weirauch U, Alb M, Weiß R, Löffler D, Kopfnagel V, Blumert C, Düll J, Scheller L, Boldt A, Vucinic V, Platzbecker U, Köhl U, Hudecek M, Reiche K. In-depth characterization of the immune microenvironment of patients undergoing CAR T cell therapy. ISCT 2023 Paris Annual Meeting, 31.5.-3.6.2023, Paris, France
• Weirauch U, Alb M, Weiß R, Löffler D, Kopfnagel V, Blumert C, Düll J, Scheller L, Boldt A, Vucinic V, Platzbecker U, Köhl U, Hudecek M, Reiche K. In-depth characterization of the immune microenvironment of patients undergoing CAR T cell therapy. 4th International Conference on Lymphocyte Engineering, 12.-14.9.2023
• Weiß R, Issmail L, Rockstroh A, Grunwald T, Fertey J, Ulbert S. Mice immunized with different recombinant West Nile virus proteins show varying levels of serological cross-reactivity and protection from infection. International Symposium on Zoonoses Research, 9.-11.10.2023, Berlin
• Wiltzsch V, Schmidt J, Dias D,  Adamowicz K, Lio CT, Arend L, Lehmann J, Hoffmann A, Lingner T, Tsoy O, Laske T, Poh P, Baumbach J, Kalkhof S. Deep proteomic profiling of diabetic bone regeneration. e:Med Omics Symposium "Metabolomics, Lipidomics, and Proteomics", 13.3.2023
• Wiltzsch V, Schmidt J, Dias D, Adamowicz K, Lio CT, Arend L, Lehmann J, Hoffmann A, Lingner T, Tsoy O, Laske T, Poh P, Baumbach J, Kalkhof S. Integrative tissue and plasma proteomics revealed liquid biopsy-accessible indicative biomarkers for impaired bone fracture healing in type 2 diabetes mellitus. eMed, 10.-11.10.2023, Berlin
• Wiltzsch V, Schmidt J, Kalkhof S. Proteomic insights into personalised polycaprolactone (PCL) scaffold-guided diabetic bone healing. DGBM, 14.-16.9.2023, Jena
• Zolnowski D, Karp S, Warncke P, Zinn J, Pannach M, Herbst R, Hänel A, Morgner A, Fricke S, Hänel M. Unicentric retrospective analysis of 130 patients with extramedullary multiple myeloma (EMM). DGHO Jahrestagung, 13.-16.10.2023, Hamburg